Day One Biopharmaceuticals announced the sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The company received the PRV following the FDA accelerated approval of OJEMDA™ (tovorafenib). The sale is a significant step for Day One, providing non-dilutive capital to strengthen its balance sheet and support the launch of OJEMDA and ongoing clinical development efforts. The Rare Pediatric Disease Priority Review Voucher Program supports initiatives for rare pediatric diseases, encouraging the development of new treatments. A portion of the proceeds from the sale will be used to fulfill obligations to Viracta Therapeutics, Inc. Day One Biopharmaceuticals is committed to redefining cancer treatment possibilities for patients of all ages, with a focus on pediatric cancer therapies like tovorafenib (OJEMDA) and pimasertib.
Day One Biopharmaceuticals Sells Priority Review Voucher for $108M, Strengthens Balance Sheet
Date:
Updated: [falahcoin_post_modified_date]